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ABSTRACT  
Drug clearance is an important pharmacokinetic 
parameter as it describes the rate of elimination of a drug 
from the body. The aim of this project was to develop a 
physiologically-based pharmacokinetic model, with the 
simulation program Simcyp, to predict the total plasma 
clearance for lorazepam for the entire paediatric age-
range. The mean prediction error for observations in 
literature were 30% or below for all ages. This model can 
be used to assess the current dosing recommendations in 
children of all ages.  
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INTRODUCTION 
Pharmacokinetics covers the process by which a drug is 
absorbed, distributed, metabolized and excreted from the 
body. Drug clearance is an important pharmacokinetic 
parameter to describe the rate of elimination of a drug,
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and is described as the volume of blood or plasma from 
which a drug is completely removed per unit of time.
2,3
 In 
paediatrics, clearance is often expressed per kg of 
bodyweight. Drugs can be cleared through different 
mechanisms, including hepatic metabolism and renal 
clearance of the unchanged drug. Hepatic metabolism 
utilizes many different enzymes. Drug clearance is an 
important factor for drug dosing: the quicker a drug is 
removed from the body, the more of this particular drug 
needs to be administrated.  
Physiologically-based pharmacokinetic modelling 
Drug research or drug dosing optimization in paediatric 
population is still challenging.
4
 There are many 
physiological changes in children that influence drug 
clearance, but this is often not systematically investigated. 
This is partly due to ethical and practical restrictions, 
making clinical trials in paediatrics very complex. To 
optimize drug treatment in paediatrics, there is need for a 
better understanding of how drugs are cleared through 
various mechanisms and how this changes with age. This 
can be achieved by the use of modelling and simulation. 
There are two basic approaches for studying clearance in 
paediatrics. The first approach is population 
pharmacokinetic modelling, which allows to empirically 
calculate pharmacokinetic parameters, such as clearance. 
Models based on this approach can be easily developed as 
they only require concentration-time data. However, 
because these models are empirical, they must be 
developed for one particular drug in one particular 
population. Thus, these models are not suitable to predict 
the pharmacokinetic of a different drug or in a different 
population. The second approach is physiologically-based 
pharmacokinetic (PBPK) modelling, which is based on 
physiological and anatomical measurements in 
combination with physicochemical drug properties. 
Unlike population models, PBPK models require a large 
amount of data, which is not always easy to obtain. 
However, because PBPK models are mechanistic, they 
can be applied to a wide range of scenarios including 
different populations or different drugs.
5
 In the paediatric 
population, adult PBPK models are scaled to children 
using maturation functions which describe the 
developmental changes from birth to adulthood. For 
instance, for drugs undergoing hepatic metabolism, 
changes in liver size and enzyme maturation are used to 
predict the paediatric clearance based on adult data.
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Enzyme maturation is implemented as a function 
describing the changes of enzyme activity or intrinsic 
clearance per gram of liver. In paediatric PBPK models, 
several maturation functions, especially those describing 
maturation of enzyme pathways, are based on very 
limited experimental data, and further research on these 
functions is needed to broaden the applicability of 
paediatric PBPK models.  
Glucuronidation 
Glucuronidation by uridine 5’-diphospho-glucuronosyl-
transferases (UGTs) is a major metabolic pathway
7
 and 
promotes the detoxification of drugs. Glucuronidation 
serves as a toxicological gatekeeper, as almost 40-70% of 
clinically used drugs are eliminated by glucuronidation.
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The mechanism of glucuronidation consists of the transfer 
of glucuronic acid to the drug molecule to increase its 
hydrophilicity, so these molecules can be easily excreted 
by the kidneys. This mechanism is carried out by several 
types of UGTs. UGTs are glycoproteins which are 
generally present in the endoplasmic reticulum of hepatic 
cells. The enzyme activity of UGTs are affected by age, 
disease state, dietary, environmental chemicals, ethnicity, 
hormonal factors and genetic polymorphisms. Genetic 
polymorphisms can lead to different metabolic 
phenotypes, such as extensive metabolisers or poor 
metabolisers. Clinically, dose adjustments might be 
required to correct for differences in metabolic clearance 
between these phenotypes. 
AIM 
The primary aim of this research project was to develop a 
PBPK model to predict the total plasma clearance for 
lorazepam for the entire paediatric age-range and evaluate 
the predictive performance of the PBPK model by 
comparing the predicted plasma clearances to values 
reported in literature. Lorazepam is a central nervous 
system active drug and is widely used for the treatment of 
epileptic seizures, anxiety disorders, and nausea and 
vomiting induced by chemotherapy.
5,9
 Lorazepam was 
especially selected for this project, because it is mainly 
metabolized by only two enzymes, namely UGT2B7 and 
UGT2B15, which allows us to study the enzyme 
maturation of these particular pathways. This research 
was part of a larger project, to optimize PBPK models in 
paediatrics, so that accurate clearance predictions for 
various drugs in children can be made.  
 
MATERIALS & METHODS 
Plasma glucuronidation clearance of lorazepam for adults 
and children were simulated with Simcyp v.13.0, which is 
an industry standard software package. In this research, 
the workflow by Maharaj et al.
5
 was adopted, to develop 
PBPK model. This model includes mathematical 
equations that describe how important parameters for 
hepatic clearance (e.g. hepatic blood flow, plasma protein 
binding) change with age. A simplified overview is 
displayed in figure 1. In a first step, adult drug clearance 
is computed using drug-specific (e.g.  pH or lipophilicity) 
and adult system-specific (e.g. liver size, hepatic blood 
flow, intrinsic clearance) parameters. Adult clearance 
predictions are compared to literature values to 
investigate the need of model adjustment. In a second 
step, a paediatric PBPK model is obtained by scaling the 
adult system-specific parameters to the paediatric 
population using maturation functions. Finally, this 
paediatric PBPK model can be used to simulate clearance 
throughout the entire paediatric population.   
 
Figure 1: Workflow outline 
For the adult PBPK model, adult intrinsic clearance 
values for UGT2B7 and UGT2B15 were derived from 
literature.
10,11
 The intrinsic clearance describes the 
metabolic rate in the absence of rate-limiting factors 
(such as hepatic blood flow or plasma protein binding). 
The adult intrinsic clearance of 1 mg of hepatic protein 
for the two UGTs were computed based on the following 
equation: 
𝐶𝐿𝑖𝑛𝑡 =  
𝑄ℎ × 𝐶𝐿ℎ
(𝑄ℎ −
𝐶𝐿ℎ
𝐵: 𝑃) × 𝑓𝑢
 
Where Qh is the hepatic blood flow (1.73 L/min), CLh is 
the  hepatic plasma clearance due to UGT2B7 or 
UGT2B15, B:P is the blood to plasma ratio (0.642 for 
lorazepam) and fu is the unbound fraction (0.11 for 
lorazepam).
5
 Adult values were used for all parameters. 
The intrinsic clearance for UGT2B15 and UGT2B7 were 
5.88 µL/min and 5.22 µL/min, respectively.  
Maturation of enzymes in the liver causes changes in 
intrinsic drug clearance. In paediatric PBPK models, 
these changes are accounted for by enzyme maturation 
functions which scale the intrinsic clearance from adults 
to children. These enzyme maturation functions describe 
the changes in intrinsic clearance (enzyme activity) with 
age expressed as percentage of the adult value. Because 
maturation of enzymes occurs at different rates, different 
maturation patterns for intrinsic clearances for UGT2B7 
and UGT2B15 were implemented in Simcyp to build the 
paediatric PBPK models. Two different paediatric models 
were developed and compared. These models have 
different maturation functions for the intrinsic clearance 
of UGT2B7 (fig 2):  
Model 1: simple linear function as standardly 
implemented in the Simcyp PBPK software package.  
Model 2: non-linear maturation pattern reported in 
literature by Edginton et al. 
12
  
Model 2 is based on newly emerging evidence regarding 
this non-linear maturation function of UGT2B7. The 
simple linear function in model 1 is derived from limited 
information and therefore model 2 is developed.
12
  
In both models the same non-linear function for 
UGT2B15 maturation defined in the Simcyp software 
(fig. 2) was implemented. For the UGT2B15 enzyme, 
multiple genotypes result in different phenotypes that 
yield different intrinsic clearances. The 2 main 
phenotypes are extensive metabolisers and poor 
metabolisers.
10
 The model assumed seventy percent of the 
individuals in the population to be extensive metabolisers, 
phenotype for which the drug is quickly eliminated from 
the body, resulting in a need for a higher dose to maintain 
a specific therapeutic concentration. Thirty percent of the 
individuals were assumed to be poor metabolisers, who 
need a lower dose to maintain a certain therapeutic 
concentration.
10
 
Figure 2: Maturation functions for UGT2B7 and UGT2B15 implemented in 
Model 1 and Model 2. Enzyme maturation functions describe the changes in 
intrinsic clearance with age and are expressed as a percentage of adult value. 
Model simulations 
Using the two developed PBPK models, plasma clearance 
predictions for lorazepam were made for the entire 
paediatric age-range, spanning from newborn up to 18-
year-old adolescents. Taking inter-individual variability 
in system-specific parameters and the reported prevalence 
of UGT2B15 extensive and poor metabolisers into 
account
10
, plasma clearance values were simulated for 
100 individuals of each age. In the simulations, the 
proportion of males and females was equal. 
The performance of the paediatric PBPK models in 
predicting lorazepam plasma clearances was evaluated 
using reported clearance values from literature.
13
 The 
percentage mean prediction error (%MPE), expressing the 
accuracy of the prediction, and the root mean square error 
(RMSE), expressing the precision of the predictions, were 
calculated by the following equations: 
%𝑀𝑃𝐸 =  
∑
(𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 − 𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑) ∗ 100
𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑
𝑛
   
 
𝑅𝑀𝑆𝐸 =  √
∑(𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 − 𝑜𝑠𝑒𝑟𝑣𝑒𝑑)2
𝑛
 
 
RESULTS AND DISCUSSION 
The mean lorazepam clearance predicted by the PBPK 
model for adults was 0.047 L/h/kg which is in agreement 
with lorazepam reported literature values.
14–16
 Thus, no 
model adjustment was needed and the adult model was 
directly used to build the paediatric models. 
Model 1 includes the simple linear function for the 
maturation of UGT2B7 enzyme activity, as implemented 
in the Simcyp software. Model 2 includes a user-defined 
non-linear maturation function for UGT2B7 borrowed 
from Edginton et al.
12
 Figure 3 shows the difference in 
lorazepam plasma clearance predicted by both models 
across the paediatric age-range. 
Figure 3: Lorazepam plasma clearance versus age predicted by Model 1 and 
Model 2.  
Table 1 shows the accuracy and precision of the 
lorazepam clearance predictions by both models. 
Clearance predictions of Model 2 were more precise 
(RMSE closer to 0) and more accurate (lower MPE%) 
than clearance predictions of Model 1 and therefore, 
Model 2 was in better agreement with the literature 
values. Both models show the best clearance predictions 
for lorazepam in children and adolescents between the 
age of 12 and 18 years. It is noteworthy that, for both 
models, the %MPE gets larger towards the lower extreme 
of the age-range. It is generally more difficult to predict 
drug clearance at very young ages, because there are 
many physiological changes taking place early in life. 
Moreover, there is limited observational data in this age-
range to compare the predictions to.
17
 
Table 1: MPE% and RMSE for lorazepam clearance values predicted by 
Model 1 and Model 2. 
Age group13 % MPE RMSE 
Model 1 Model 2 Model 1 Model 2 
Study 1: Neonates -59.76 -24.90 0.012 0.009 
Study 2: Children -51.25 -26.59 0.037 0.019 
Study 3: Children -53.73 -30.32 0.031 0.023 
Study 4: Adolescents -18.92 8.05 0.012 0.005 
Study 5: Adolescents -20.29 -10.61 0.014 0.006 
Study 6: Adolescents -19.58 -11.29 0.011 0.007 
 
The results show a clear improvement of lorazepam 
plasma clearance predictions for Model 2. In fig. 4 
individual PBPK clearance predictions of Model 2 and 
the geometric mean of these predictions are shown, 
together with reported clearances from literature.
13
 
Because clearances from literature were expressed per kg, 
predicted and literature clearances are presented together 
versus body weight. Clearance values predicted by Model 
2 steeply increase with body weight in new-borns and 
infants, as can be seen in fig. 4. The clearance predictions 
remain stable after a bodyweight of approximately 15 kg 
is attained. The predictions are in reasonable agreement 
with the observations with %MPE at or below 30% 
across the entire age-range. 
Figure 4: Overview of lorazepam clearance values, including individual 
PBPK predictions and geometric mean of these predictions by Model 2, and 
mean observed values reported in literature.13 
 
FURTHER RESEARCH 
Many maturation functions in paediatric PBPK models 
are not well characterized and this study shows that 
discrepancies between enzyme maturation functions do 
impact the accuracy and precision of clearance 
predictions in the paediatric population. Therefore 
optimization and validation of maturation functions is an 
essential step in the development of paediatric PBPK 
models.  
The optimized PBPK model herein can be used to assess 
the current dosing recommendations in children of all 
ages. In this assessment it is important to take the 
UGT2B15 phenotype into consideration as well. The 
different phenotypes for UGT2B15 are important and 
have an impact on the clearance of lorazepam and maybe 
other drugs in paediatrics. By taking into account 
different phenotypes of the UGT2B15 enzyme together 
with their prevalence in the population, the impact of 
these phenotypes on drug clearance in children can be 
further studied. This is necessary to determine whether 
dose adjustments are required for particular phenotypes. 
Additionally, an evaluation of the current dosing 
recommendations could be performed.  
 
CONCLUSION 
This study improved the maturation function of the 
intrinsic clearance of the UGT2B7 enzyme in a PBPK 
model for children of all ages, thereby improving 
lorazepam clearance predictions. By using an optimized 
maturation function for UGT2B7, this PBPK model and 
the clearance predictions are improved. Due to the 
generalizability of PBPK models, clearance prediction for 
other UGT2B7 substrates will likely improve as well.  
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